Goodbye 30% fertility plateau.
Incintas is about to replace you with much better odds to achieve pregnancy in assisted reproduction.
INCINTAS THERAPEUTICS, INC.
Addresses the Main Hurdle in Achieving Pregnancy in Assisted Reproduction by Redefining the Way We Prepare the Uterus in Assisted Reproductive Technologies (ART), using Sustained and
Controlled Release Targeted Intrauterine Therapeutics
What is Known:
It is imperative for the "Window of Implantation" to be open in order for pregnancy to be achieved both in healthy pregnancy and in ART, (including IVF, IUI, AI and timed intercourse treatment). When this window is closed, pregnancy is impossible because the embryo cannot implant into the uterine lining.
Did you know?
The current Implantation Window in ART
is only "open" for 24 hours on average, compared to 4-5 days in healthy pregnancy? This fact is clinically validated and more importantly, the rate-limiting factor in achieving
live birth rate in assisted reproduction.
DISCOVERY:
When exogenous progesterone is administered and reaches an ideal concentration range within uterine tissue, pregnancy occurs more than 80% of the time. Endometrial receptivity is a function of the proper concentration of progesterone within the uterine lining. Failed pregnancy is the result of too little or too much progesterone within the uterus. There exists a very narrow hormonal concentration range in order to achieve ideal pregnancy outcome (80%+ per transfer).
These findings are clinically validated using endometrial biopsy analysis,
(ER-Map/ER-Grade, Enciso, et. al., 2016/2018).
Incintas Therapeutics has patented a novel Intrauterine Route of Administration in assisted reproduction
to sustain and control the ideal concentration of progesterone within uterine tissue to replicate clinical findings and corner the market of this advanced means of uterine preparation and improved fertility outcome. For the first time in assisted reproduction we now know how to directly modulate endometrial receptivity using controlled release therapeutics.
About Us
WHAT WE DO
"We intend to move the needle pretty far in assisted reproduction by focusing upon failed implantation."
Incintas Therapeutics is comprised of an accomplished team of scientists, physicians, geneticists and business professionals who are focused upon improving pregnancy outcome in reproductive medicine.
Our sole purpose is to resolve the problem of failed embryonic implantation (the main hurdle in achieving pregnancy in IVF) to ultimately encourage Single Embryo Transfer (SET) which is more likely to result in a healthy singleton pregnancy for the infertile couple.
Graphical Analysis
Human IM and PV endometrial biopsy data vs. the Incintas Intrauterine Progesterone Advantage
Mitchell V. Pizolato,
Nov. 23 -Nov. 29, 2000.
Multiple IVF Birth
Lance D. Pizolato
Nov. 23 - Dec. 1, 2000
Multiple IVF Birth
Rest in Peace, my dear sons.
